LYRA THERAPEUTICS INC
LYRA
LYRA was delisted on the 16th of March, 2026.
54 hedge funds and large institutions have $5.54M invested in LYRA THERAPEUTICS INC in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 15 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
0.17% less ownership
Funds ownership: 0.99% → 0.82% (-0.17%)
13% less funds holding
Funds holding: 62 → 54 (-8)
34% less capital invested
Capital invested by funds: $8.36M → $5.54M (-$2.82M)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$117K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$88K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$75.3K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$53.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$25.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.05M |
| 2 |
SEI Investments
Oaks,
Pennsylvania
|
-$201K |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$179K |
| 4 |
Morgan Stanley
New York
|
-$95.9K |
| 5 |
EFG
Everhart Financial Group
Dublin,
Ohio
|
-$64.9K |
LYRA Hedge Fund Activity: Q4 2024 in Review
54 of the 7,594 institutional investors tracked by Wall St. Rank reported a position in LYRA THERAPEUTICS INC (LYRA) for Q4 2024, worth a combined $5.54M — down 34% from $8.36M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LYRA and 8 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 20 added.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $117K. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.05M sold.
- 54 institutional investors held LYRA THERAPEUTICS INC (LYRA) as of Q4 2024, down from 62 in Q3 2024.
- Funds reported $5.54M of LYRA THERAPEUTICS INC stock for Q4 2024, down 34% quarter-over-quarter.
- 8 funds opened new LYRA THERAPEUTICS INC positions in Q4 2024 and 15 closed out, a net change of -7 holders.
- The largest LYRA THERAPEUTICS INC buyer in Q4 2024 was ADAR1 Capital Management, an estimated $117K added.
- The largest LYRA THERAPEUTICS INC seller in Q4 2024 was Citadel Advisors, an estimated $1.05M sold.
Based on aggregated 13F filings for Q4 2024.